Molecular Profiling of Vascular Remodeling in Chronic Pulmonary Disease
Overview
Authors
Affiliations
Pulmonary hypertension and pulmonary vascular remodeling (PVR) are common in many lung diseases leading to right ventricular dysfunction and death. Differences in PVR result in significant prognostic divergences in both the pulmonary arterial and venous compartments, as in pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease (PVOD), respectively. Our goal was to identify compartment-specific molecular hallmarks of PVR, considering the risk of life-threatening pulmonary edema in PVOD, if treated by conventional pulmonary hypertension therapy. Formalin-fixed and paraffin-embedded tissues from fresh explanted human lungs of patients with PVOD (n = 19), PAH (n = 20), idiopathic pulmonary fibrosis (n = 13), and chronic obstructive pulmonary disease (n = 15), were analyzed for inflammation and kinome-related gene regulation. The generated neuronal network differentiated PVOD from PAH samples with a sensitivity of 100% and a specificity of 92% in a randomly chosen validation set, a level far superior to established diagnostic algorithms. Further, various alterations were identified regarding the gene expression of explanted lungs with PVR, compared with controls. Specifically, the dysregulation of microtubule-associated serine/threonine kinase 2 and protein-o-mannose kinase SGK196 in all disease groups suggests a key role in pulmonary vasculopathy for the first time. Our findings promise to help develop novel target-specific interventions and innovative approaches to facilitate clinical diagnostics in an elusive group of diseases.
The role of vascularity and the fibrovascular interface in interstitial lung diseases.
Dietrich J, Kang A, Tielemans B, Verleden S, Khalil H, Langer F Eur Respir Rev. 2025; 34(175).
PMID: 39909504 PMC: 11795288. DOI: 10.1183/16000617.0080-2024.
Jeremiasen I, Peruzzi N, Lampei E, Meyer S, Akyurek L, Gebre-Medhin E Pulm Circ. 2024; 14(4):e70024.
PMID: 39678731 PMC: 11638014. DOI: 10.1002/pul2.70024.
Pathology and pathobiology of pulmonary hypertension: current insights and future directions.
Guignabert C, Aman J, Bonnet S, Dorfmuller P, Olschewski A, Pullamsetti S Eur Respir J. 2024; 64(4).
PMID: 39209474 PMC: 11533988. DOI: 10.1183/13993003.01095-2024.
Dissecting the lung transcriptome of pulmonary fibrosis-associated pulmonary hypertension.
Brownstein A, Mura M, Ruffenach G, Channick R, Saggar R, Kim A Am J Physiol Lung Cell Mol Physiol. 2024; 327(4):L520-L534.
PMID: 39137526 PMC: 11482468. DOI: 10.1152/ajplung.00166.2024.
Inhalation of hydrogen gas protects against mitomycin-induced pulmonary veno-occlusive disease.
Zhang C, Xing Y, Wu X, Jiang Q, Luo X, He W Respir Res. 2024; 25(1):281.
PMID: 39014440 PMC: 11253336. DOI: 10.1186/s12931-024-02906-y.